Find Locations
For hours, walk-ins and appointments.
Nonclinical Studies
Breakthroughs in the making start here.
Plan your next nonclinical study or partner with us for an IND-/CTA-enabling package to get you from research to clinical trials faster.
Nonclinical Capabilities
Search our online catalog
Find nonclinical assays and studies in our online catalog, including:
The Power of Connected Insights
The landscape of development is becoming more complex. By connecting inspiring science with data, our committed scientific teams uncover insights from preclinical and clinical studies to help you reach your early development milestones.
Solutions to propel your nonclinical
program from discovery to the clinic
20+
global nonclinical lab sites,
with ~8 million sq.ft. space
180+
integrated IND-/CTA-enabling
programs initiated per year
Nonclinical facilities and locations
Enjoy global support and capacity for your nonclinical and preclinical studies with labs strategically positioned around the world.
Marketplace
Your partnering journey starts now.
Start strategic conversations that kick-start partnering with the help of MarketPlace by Labcorp. One connection is made every month in our complimentary innovative platform that connects asset providers and asset seekers. Learn how MarketPlace can propel your path forward.
Early development investments
Making your breakthroughs possible with investments that matter
See how Labcorp is investing worldwide in nonclinical development and how these innovations all started by listening to you and appreciating your changing requirements.
Disease models
Oncology models and cell lines
Advance your preclinical oncology compounds with a comprehensive suite of preclinical oncology studies, including in vitro and in vivo pharmacology efficacy models, in vivo imaging technologies as well as focal radiation capabilities.
Administration route
Inhalation testing capabilities
Inhalation toxicology studies are becoming vital in assessing the safety and potential toxicity of inhaled drugs or chemicals as respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) become more common.
Programmatic development
IND-/CTA-enabling packages
Accelerate your molecule’s success with early phase development solutions that help to advance your molecule swiftly through critical milestones while maximizing the asset's value. Shave off as much as 30% on your early drug development timeline.
